Therefore, according to experience from our Institution early initiation of ACE inhibitors or ARB appears to be safe in carefully selected recipients with relatively good early graft function. doi: 10.1002/14651858.CD007751.pub2.Tantisattamo E, Molnar MZ, Ho BT, Reddy UG, Dafoe DC, Ichii H, Ferrey AJ, Hanna RM, Kalantar-Zadeh K, Amin A.Front Med (Lausanne). 2009 Nov;22(11):1073-80. doi: 10.1111/j.1432-2277.2009.00922.x. 2019 Jun;57(6):275-283. doi: 10.5414/CP203359. The preferable choice of antihypertensives that should be used in patients after kidney transplantation remains a matter of debate; however, calcium channel blockers (CCB) and angiotensin-converting enzyme inhibitors (ACEI) are currently the most commonly used antihypertensives. Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, Oberbauer R.J Am Soc Nephrol. This site needs JavaScript to work properly. COVID-19 is an emerging, rapidly evolving situation. ACEI/ARB decreased proteinuria (P < 0.001) and lowered haemoglobin (P = 0.002), but the haemoglobin change requires no additional treatment (from 119-131 g/L to 107-123 g/L). Name must be less than 100 characters The aim of the present paper is to evaluate the efficiency and safety of early (within six months post-transplantation) versus late (after six months post-transplantation) initiation of ACE-inhibitors or ARB in RTRs. Published by Elsevier Taiwan. 2018 Jan;34(1):1-13. doi: 10.1016/j.kjms.2017.07.007. Wenting GJ, Tan-Tjiong HL, Derkx FH, et al. Wiley Clipboard, Search History, and several other advanced features are temporarily unavailable. Epub 2006 Feb 15.Hernández D, Muriel A, Abraira V, Pérez G, Porrini E, Marrero D, Zamora J, González-Posada JM, Delgado P, Rufino M, Torres A.Nephrol Dial Transplant. Please enable it to take advantage of the complete set of features! 2016 Mar 5;129(5):562-9. doi: 10.4103/0366-6999.176987.Clin Transplant. eCollection 2020. Unable to load your delegates due to an error This site needs JavaScript to work properly. 2017 Apr;31(4). Effect of renin-angiotensin system inhibitors on survival in kidney transplant recipients: A … The role of renin-angiotensin system inhibitors (ACE-inhibitors) or angiotensin receptor blockers (ARB) in the renal transplant recipients (RTRs) is incompletely defined and according to the current guidelines they should be initiated after six months post-transplantation. The mainstay of treatment is ACE inhibitors (ACEi) or angiotensin II receptor blockers (ARB), but seldom phlebotomy. Unable to load your delegates due to an error 2007 Sep;29(9):1803-24. doi: 10.1016/j.clinthera.2007.09.019.Ehlken B, Shlaen M, Lopez Fuensalida de Torres MDP, Hisada M, Bennett D.Int J Clin Pharmacol Ther. Post-transplant erythrocytosis (PTE) is a condition with elevated haematocrit (hct) in renal allograft recipients. The study group compromised of 108 RTRs (50 male and 58 female) who received a kidney transplant. Epub 2017 Feb 22.Sharma P, Blackburn RC, Parke CL, McCullough K, Marks A, Black C.Cochrane Database Syst Rev. Treatment of CHF: ACE-Inhibitors and ARBs in the Kidney Transplant Populaon KDIGO. In the 54 (50%) of the 108 patients ACE inhibitors/ARB were initiated within six months post-transplantation and in 49 (90.7%) of them within three months (in 29 patients within one month; in 13 within two months; in 7 within 3 months) post-transplantation. Copyright © 2017. For this analysis purpose, recipients were stratified into two groups according to the time of ACE inhibitors/ARB initiation into early (within six months post-transplantation) and late (after six months after transplantation) group. For each patient haemoglobin, serum creatinine and potassium levels were analyzed at the beginning of ACE inhibitors/ARB introduction and at the end of the first, third, sixth and twelfth month. Epub 2011 May 28.Chin Med J (Engl). N=70 Paents with Persistent LVH 6-12 Months Post-Transplant Randomized to Lisinopril or No Therapy Furthermore, the benefit of ACEI/ARB on patient survival (RR = 0.62; 95%CI:0.47-0.83) and graft survival (RR = 0.58, 95%CI:0.47-0.71) was limited to those with ≥3years' follow-up. Epub 2007 Dec 19.Transplant Proc. Pooled results showed that ACEI/ARB was associated with decreased risks of patient death (relative risk [RR] = 0.64; 95% confidence interval [CI]:0.49-0.84) and graft loss (RR = 0.59; 95%CI:0.47-0.74). It is widely known that patients with CKD have increased risk for CVD, though there is little data examining the effects of RAAS inhibitors on CVD in this population.¹ A recent study found a reduced risk for fatal CVD in peritoneal dialysis patients treated with ACEis. 2008 Jan;42(1):116-20. doi: 10.1345/aph.1K471. 2011 Oct 5;(10):CD007751. We therefore concluded that ACEI/ARB treatment may reduce patient death and graft loss, but additional well-designed prospective studies are needed to validate these findings. Acute renal thrombosis induced by angiotensin-converting enzyme inhibitors in patients with renovascular hypertension. There was no statistically significant difference between the two groups related to age or gender and due to the duration of dialysis treatment before the transplantation.